Please login to the form below
Intercept
This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.
Merck enters agreement with Hanmi for investigational NASH drug
Intercept Pharmaceuticals is awaiting a US Food and Drug Administration (FDA) review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again
Latest news
-
Genfit scraps phase 3 trial of experimental NASH drug
Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in
-
Zydus Cadila scores first ever NASH approval, in India
Another potential treatment for NASH – from Intercept – is currently under review with the US Food and Drug Administration (FDA). ... additional information provided in response to FDA requests,” Intercept wrote in the filing at the time.
-
FDA delays decision on Intercept's NASH drug by three months
Intercept confirmed the delay in a filing with the US Securities &Exchange Commission last week. ... additional information provided in response to FDA requests,” Intercept wrote in the filing.
-
Boehringer bolsters NASH pipeline with Enleofen link-up
Meanwhile, Intercept Pharma’s obeticholic acid (OCA) is under priority review at the FDA for the treatment of liver fibrosis due to NASH, and could become the first drug to treat
-
Provention Bio wins PRIME designation for type 1 diabetes prevention drug
1R inhibition intercepts the migration of inflammatory cells to the gut.
More from news
Approximately 10 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of precision medicine in oncology
In this endeavour to eradicate or intercept cancer, it is our duty to account for distinct differences in people’s ‘-omics’ spectrum, but also importantly in their clinical, psychosocial and professional
-
Deal Watch June 2016
In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Simon Doyle joins STEM
Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
-
Glenn Sblendorio to retire as president of The Medicines Company
He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Pharma, Technology, and Healthcare in the New Normal
In this episode of Impetus Digital's Fireside Chat, I talk to Brian Canestraro, General Manager at Intercept Pharmaceuticals.
-
Blog: 5 ingredients: Multichannel marketing, simplified
Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
-
Market Insights Can Deliver a Better Patient Experience
Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- Novavax to provide 1.1 billon COVID-19 vaccine doses to COVAX
- Enabling Patient-Focused Research Through Virtual Clinical Trials
- Innovative Approaches to Managing Mental Health Conditions
- Newcells Biotech secures over £5m for 3D tissue models
- FDA briefing document backs J&J’s one-dose COVID-19 vaccine
- Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds
- Moderna announces plans for COVID-19 variant-specific booster jabs and new production targets
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
- #DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
- Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....
Quick links
Infographics
